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Lack of voltage-dependent anion channel in
human mitochondrial myopathies
SIR&mdash;In several hundreds of patients with a mitochondrial
myopathy an enzyme defect in mitochondrial energy
metabolism is identified. However, in a substantial number
of subjects no enzyme defect can be detected, although
diminished substrate oxidation and ATP production rates
are found in their muscle in vitro. The hypothesis, that in
this group of patients proteins for transport of various ions
and substrates across mitochondrial membranes might be
affected, led us to study these transport proteins more
systematically. Among 40 investigated patients, 1 was found
with a diminished content of the voltage-dependent anion
channel (VDAC or human porin).
Figure: Immunoblots with VDAC and ANT antisera
Samples of muscle 600 g supernatants from patient (lanes 4) and 3
controls (lanes 3, 5, 6) were dissolved in sodium dodecylsulphate and
loaded on polyacrylamide gels (10-15% gradient), together with
biotinylated molecular weight markers (lanes 1: 39-8, 29-0, 20.1 kDa)
and purified ANT (lanes 2: 29 kDa). All lanes of controls and patient
contained 100 mU cytochrome c oxidase (the patient’s muscle had
normal cytochrome c oxidase activity). After electrophoresis (Phast
System, Pharmacia-LKB, Woerden, Netherlands) proteins were
electroblotted to nitrocellulose. Immunolabelling of the proteins was
done with 4 different antibodies: human B-lymphocyte VDAC monoclonal
antibodies from 2 different cell lines (mAb-No 4 in panel I and mAb-No 6
in panel 11),’ anti-bovine heart VDAC2 (panel III), and anti-C-terminal
bovine heart ANT3 (panel IV). Immunodetection was done applying the
Biotin-ECL method (Amersham International, UK).
The patient was born at term from non-consanguineous
parents. He had dysmorphism, hypotonia, respiration and
feeding problems, and seizures. He was treated for
hypothyroidism. Because of lactic acidosis a quadriceps
muscle biopsy specimen was taken at the age of 2 years.
Decreased rates of pyruvate and malate oxidation and of
ATP production were found. The content of the membrane
transport proteins VDAC and ATP/ADP translocator
(ANT) were estimated immunochemically. The amount of
VDAC protein (35 kDa, marked by -v- in figure) appeared
to be clearly decreased, with use of monoclonal anti-N-
terminal human VDAC (figure; panels I, II), and polyclonal
anti-bovine-heart VDAC (panel III) antibodies. The
ANT content (29 kDa, marked by -A-) appeared to be
slightly reduced. The polyclonal antiserum also reacted
with other supernatant proteins (panel III). In this panel
the VDAC deficiency of the patient was additionally
confirmed: apart from the VDAC protein the amounts
of all proteins, including ANT, were similar to those in
controls.
To our knowledge, this case is the first in which a
lack of VDAC protein has been shown in human pathology.
The detailed function of VDAC is still under investigation.
VDAC is a pore-forming protein in the outer mitochondrial
membrane, which at low transmembrane voltage is open
for anions such as phosphate, chloride, and adenine
nucleotides. At higher transmembrane voltage or in the
presence of VDAC-modulating proteins VDAC can function
as a selective channel for cations and uncharged molecules.4
These features make VDAC likely to play a regulatory
role in mitochondrial energy metabolism.5 The lack of
VDAC might cause a bottleneck in the outer membrane
of the patient’s muscle mitochondria with respect to
ADP and/or inorganic phosphate transport inwards, or
ATP transport outwards, thereby disturbing energy
metabolism.
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No aspirin in red wine
SIR-Muller and Fugelsang (June 4, p 1428) suggest that
wine is a good source of salicylic acid and that this may
explain a preventive effect in cardiovascular diseases. We
measured salicylic and acetylsalicylic acid in red Bordeaux
wines (Rineau 1993, Lavergne 1993, and Mondetour, 1992)
with high-performance liquid chromatography and a highly
specific fluorescence detection method. The method was
validated by varing extraction conditions, mainly extraction
solvents and extraction time. In red wine we found 0-7 mg
salicylic acid per litre and no acetylsalicylic acid (detection
limit 0-025 mg/L). Thus, by contrast with Muller and
Fugelsang we found negligible amounts of (acetyl)salicylic
acid in wine. Even if wine did contain larger amounts of
salicylic acid this would not be expected to affect
cardiovascular risk. Salicylic acid and dihydroxybenzoic
acids do not affect thromboxane B formation and platelet
aggregation; this specifically requires acetylsalicylate
(aspirin), which inactivates cyclo-oxygenase by irreversible
acetylation.’ 1
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CORRECTION
Effect of simvastatin on coronary atheroma-In figure 1 of the article by
MAAS investigators (3 Sept, p 633), the indicators for placebo and
simvastatin were incorrect. Placebo is represented by open circles
connected by solid lines and simvastann by filled circles connected by
interrupted lines.
